| Trial ID: | L2122 |
| Source ID: | NCT06825182
|
| Associated Drug: |
Outpatient Newly Diagnosed Type 2 Diabetes Subjects
|
| Title: |
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Outpatient newly diagnosed type 2 diabetes subjects|DRUG: Inpatient newly diagnosed type 2 diabetes subjects
|
| Outcome Measures: |
Primary: Glucagon levels, Compare the glucagon levels in diabetic subjects during hyperglycemia and hypoglycemia, and the changes in GCG after 3 months of GLP-1RA treatment, 19 months |
|
| Sponsor/Collaborators: |
Sponsor: Nanjing First Hospital, Nanjing Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
1000
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-11-07
|
| Completion Date: |
2025-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-13
|
| Locations: |
Nanjing First Hostital, Nanjing, Jiangsu, 210000, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06825182
|
